Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics
Executive Summary
New US FDA draft guidance says that the agency will no longer change the proper names of originator biologics to include a four-letter suffix, although the agency will continue to attach suffixes to future approvals.